22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc. ’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4,...
19:11 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Aurinia starts Phase III AURORA trial of voclosporin for lupus nephritis

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) began the Phase III AURORA trial evaluating Luveniq voclosporin (LX211) to treat lupus nephritis. The double-blind, international trial will enroll about 320 patients to receive twice-daily 23.7 mg voclosporin plus...
15:46 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Voclosporin regulatory update

Aurinia said it believes results from the planned Phase III AURORA trial and the completed Phase IIb AURA-LV trial of voclosporin will be sufficient for regulatory submissions of the product in the EU and Japan...
23:42 , Apr 7, 2017 |  BC Extra  |  Company News

Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed Phase IIb study of voclosporin ( LX211 ) will be sufficient for regulatory submissions in the EU...
20:09 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

Voclosporin: Additional Ph IIb AURA-LV data

Additional data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 and 39.5 mg oral voclosporin plus standard of care (SOC) mycophenolate mofetil (MMF) and...
20:41 , Mar 2, 2017 |  BC Extra  |  Clinical News

Aurinia bounces on latest lupus nephritis readout

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) shares jumped after the company said both doses of voclosporin ( LX211 ) met the 48-week secondary efficacy endpoints in the Phase IIb AURA-LV trial to treat active lupus nephritis,...
21:34 , Dec 2, 2016 |  BioCentury  |  Product Development

New day for nephrons

Updated data on Aurinia Pharmaceuticals Inc. ’s voclosporin suggest the calcineurin inhibitor could get more lupus nephritis patients into remission faster than current therapies while reducing reliance on toxic standards of care. But first the...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Luveniq voclosporin: Phase IIb data

Top-line data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 mg oral voclosporin plus standard of care (SOC) mycophenolate mofetil (MMF) and oral corticosteroids...
07:00 , Aug 15, 2016 |  BC Extra  |  Clinical News

Aurinia sinks on Phase IIb lupus nephritis results

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) lost more half its value Monday after reporting data from the Phase IIb AURA-LV study of voclosporin ( LX211 ) to treat active lupus nephritis (LN). Although one of the...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Luveniq voclosporin: Clinical trial preliminary data

Preliminary data from 7 patients with active lupus nephritis in the open-label, Malaysian AURION trial showed that twice-daily 23.7 mg oral voclosporin plus mycophenolate mofetil (MMF) and oral corticosteroids led to 4 cases of complete...